Cypherpunk Technologies, backed by the Winklevoss twins, reported first-half results in the red with 37.8 million dollars in net losses. Its cash reserves dropped to 7.6 million dollars as of June 30, down from 14 million at the end of 2025. The Nasdaq-listed company, trading under the symbol CYPH, announced a pivot toward developing an anti-cancer drug, Sirexatamab (DKN-01), targeting colorectal cancer and granted FDA fast track designation. Cypherpunk holds 323,394 ZEC (1.92% of circulating supply), with an average purchase price of 341.84 dollars versus a current price around 489 dollars. CYPH shares trade at approximately 0.69 dollar, down 40% year-over-year, with a market cap of 74 million dollars, well below the value of its ZEC treasury.
Source: Read the original article
